Crestor, sometimes referred to as a “super statin”, is the strongest drug available for the treatment of high cholesterol. A condition called rhaddomyolysis is a possible side effect of most statins. This occurs when muscle tissue breaks down and myoglobin is released into the bloodstream, sometimes resulting in kidney failure. Research suggests that the risk of developing rhaddomyolysis increases with higher doses of statins. Studies also show that the following patients are at a greater risk for this condition: Asian-Americans, people taking immune suppressing drugs, and people with severe kidney disease. In 2005 the FDA issued a health advisory addressing both the risks and benefits associated with the use of Crestor. The manufacturer was required to revise the prescription label to include all the possible risks and recommended doses for patients most susceptible to developing these serious side effects.